DeepMed Research

Columbia University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1754-01-01

Employees: 20.8K

Market Cap: -

Website: https://www.arch.columbia.edu

Clinical Trials

Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA

Recruiting

Conditions: Spinal Muscular Atrophy

First Posted Date: 2025-05-02

Last Posted Date: 2025-05-02

Lead Sponsor: Columbia University

Target Recruit Count: 45

Registration Number: NCT06955897

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Biventricular Remodeling in Transcatheter Tricuspid Valve Replacement - Acute Hemodynamic Instability Study

Conditions: Tricuspid Regurgitation
Heart Failure
Structural Heart Disease
Interventional Cardiology

First Posted Date: 2025-05-02

Last Posted Date: 2025-05-14

Lead Sponsor: Columbia University

Target Recruit Count: 140

Registration Number: NCT06954792

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Navigating Financial and Health-Related Social Needs in Adolescent and Young Adult Cancer Survivors (AYA-NAV)

Not Applicable

Recruiting

Conditions: Cancer in Adolescence

First Posted Date: 2025-04-30

Last Posted Date: 2025-04-30

Lead Sponsor: Columbia University

Target Recruit Count: 120

Registration Number: NCT06950983

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Project Orleu: Reducing Intersectional and HIV Stigma Among Health Care Providers and High Risk Women Who Use Drugs in Kazakhstan

Not Applicable

Active, not recruiting

Conditions: Stigma, Social

First Posted Date: 2025-04-17

Last Posted Date: 2025-04-17

Lead Sponsor: Columbia University

Target Recruit Count: 83

Registration Number: NCT06932796

Locations: 🇰🇿
Global Health Research Center for Central Asia, Almaty, Kazakhstan

R-MVST Cells for Treatment of Viral Infections in Children and Young Adults

Phase 1

Not yet recruiting

Conditions: Epstein-Barr Virus
Cytomegalovirus Infections
Adenovirus
BK Virus Infection
Immune Deficiency

Interventions: Drug: Rapidly generated virus specific T (R-MVST) cells

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Columbia University

Target Recruit Count: 18

Registration Number: NCT06926894

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Moms and Babies Health and Well-being

Not Applicable

Recruiting

Conditions: Maternal and Child Health Outcomes

First Posted Date: 2025-04-11

Last Posted Date: 2025-04-11

Lead Sponsor: Columbia University

Target Recruit Count: 1250

Registration Number: NCT06923371

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Transcranial Direct Current Stimulation for Post Treatment Lyme Disease

Not Applicable

Recruiting

Conditions: Post-Treatment Lyme Disease

First Posted Date: 2025-04-08

Last Posted Date: 2025-04-08

Lead Sponsor: Columbia University

Target Recruit Count: 55

Registration Number: NCT06915324

Locations: 🇺🇸
Columbia University Department of Psychiatry, New York, New York, United States

RFA for Superficial Lipomas

Not Applicable

Recruiting

Conditions: Lipoma

First Posted Date: 2025-03-30

Last Posted Date: 2025-03-30

Lead Sponsor: Columbia University

Target Recruit Count: 10

Registration Number: NCT06903208

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Ending the Epidemic Interventions in the Dental Setting - UH3

Not Applicable

Not yet recruiting

Conditions: HIV-1-infection

First Posted Date: 2025-03-24

Last Posted Date: 2025-03-24

Lead Sponsor: Columbia University

Target Recruit Count: 128

Registration Number: NCT06890988

Locations: 🇺🇸
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States
🇺🇸
Weill Cornell Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States
🇺🇸
NYP-Queens, Queens, New York, United States

Evaluating the Long-term Safety and Tolerability of Imatinib in Patients with Lymphangioleiomyomatosis (LAM)

Phase 1

Recruiting

Conditions: Lymphangioleiomyomatosis (LAM)
Lymphangioleiomyomatosis

Interventions: Drug: Imatimib Mesylate
Drug: Placebo

First Posted Date: 2025-03-21

Last Posted Date: 2025-03-24

Lead Sponsor: Columbia University

Target Recruit Count: 20

Registration Number: NCT06889168

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy